ReviewScience China. Life sciences2020
Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?
Review in Science China. Life sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 42 citations in OpenAlex.
- The Critical Role of Pulse Oximetry Screening for Congenital Heart Disease and Patent Ductus Arteriosus in Newborns.Cureus · 2024Article
- Longitudinal dynamic single-cell mass cytometry analysis of peripheral blood mononuclear cells in COVID-19 patients within 6 months after viral RNA clearance.BMC infectious diseases · 2024Article
- Immunological characterization and comparison of children with COVID-19 from their adult counterparts at single-cell resolution.Frontiers in immunology · 2024Article
- Innovation-driven trend shaping COVID-19 vaccine development in China.Frontiers of medicine · 2023Review
- Current progress in the development of prophylactic and therapeutic vaccines.Science China. Life sciences · 2023Review
- Peptide microarray analysis of in-silico predicted B-cell epitopes in SARS-CoV-2 sero-positive healthcare workers in Bulawayo, Zimbabwe.Acta tropica · 2023Article
- Immune responses in mildly versus critically ill COVID-19 patients.Frontiers in immunology · 2023Review
- The functional views on response of host rabbit post coronavirus vaccination via ACE2 PET.American journal of nuclear medicine and molecular imaging · 2023Article
- An antibody cocktail with broadened mutational resistance and effective protection against SARS-CoV-2.Science China. Life sciences · 2023Article
- Impact of inactivated COVID-19 vaccines on viral shedding in B.1.617.2 (Delta) variant-infected patients.Science China. Life sciences · 2022Article
- Receipt of inactivated COVID-19 vaccine had no adverse influence on embryo implantation, clinical pregnancy and miscarriage in early pregnancy.Science China. Life sciences · 2022Article
- A urinary proteomic landscape of COVID-19 progression identifies signaling pathways and therapeutic options.Science China. Life sciences · 2022Article
- Application of IgG antibody titer and subtype in diagnosis and severity assessment of hemolytic disease of the newborn.Translational pediatrics · 2022Article
- Immunoinformatic paradigm predicts macrophage and T-cells epitope responses against globally conserved spike fragments of SARS CoV-2 for universal vaccination.International immunopharmacology · 2022Article
- Coiled-coil heterodimer-based recruitment of an exonuclease to CRISPR/Cas for enhanced gene editing.Nature communications · 2022Article
- Potential of Microneedle Systems for COVID-19 Vaccination: Current Trends and Challenges.Pharmaceutics · 2022Review
- A quantitative assay for detection of SARS-CoV-2 neutralizing antibodies.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2022Article
- COVID-19 Vaccines and Public Anxiety: Antibody Tests May Be Widely Accepted.Frontiers in public health · 2022Article
- Dynamics of anti-SARS-CoV-2 antibodies in repeat convalescent plasma donors.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2021Article
- Stability of SARS-CoV-2 on the Surfaces of Three Meats in the Setting That Simulates the Cold Chain Transportation.Virologica Sinica · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected millions of people and caused tremendous morbidity and mortality worldwide. Effective treatment for coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 infection is lacking, and different therapeutic strategies are under testing. Host humoral and cellular immunity to SARS-CoV-2 infection is a critical determinant for patients' outcomes. SARS-CoV-2 infection results in seroconversion and production of anti-SARS-CoV-2 antibodies. The antibodies may suppress viral replication through neutralization but might also participate in COVID-19 pathogenesis through a process termed antibody-dependent enhancement. Rapid progress has been made in the research of antibody response and therapy in COVID-19 patients, including characterization of the clinical features of antibody responses in different populations infected by SARS-CoV-2, treatment of COVID-19 patients with convalescent plasma and intravenous immunoglobin products, isolation and characterization of a large panel of monoclonal neutralizing antibodies and early clinical testing, as well as clinical results from several COVID-19 vaccine candidates. In this review, we summarize the recent progress and discuss the implications of these findings in vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.